Business
Director's Commitments
Director's Commitments.
About this update from Hikma Pharmaceuticals Plc
[{"type":"text","content":"\n Hikma Pharmaceuticals Plc\n06 December 2006\n\n\n Update on Non-Executive Director's Appointments\n\nLONDON, 6 December 2006 - Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK), the\nmultinational pharmaceuticals group, announces that Michael Ashton, a\nnon-executive Director and Chairman of the Remuneration Committee, has been\nappointed as the Chief Executive Officer of LMA International NV, a Singapore\nlisted company.\n\n - ENDS -\nEnquiries:\n\nHikma Pharmaceuticals PLC\nSusan Ringdal +44 20 7399 2760\nInvestor Relations Director\n\nBrunswick Group\nJon Coles / Justine McIlroy / Alex Tweed +44 20 7404 5959\n\nAbout Hikma\nHikma Pharmaceuticals PLC is a multinational pharmaceutical group focused on\ndeveloping, manufacturing and marketing a broad range of both branded and\nnon-branded generic and in-licensed pharmaceutical products. Hikma's operations\nare conducted through three businesses: Generic, Branded and Injectable\nPharmaceuticals. Hikma's operations are based principally in the United States,\nthe Middle East and North Africa ('MENA') region and Europe. In 2005, the Group\nhad revenue of $262 million and profit attributable to shareholders of $44\nmillion. At 31 December 2005, the Group had over 1,800 employees. For news and\nother information, please visit www.hikma.com.\n\n\n\n\n This information is provided by RNS\n The company news service from the London Stock Exchange\n \n ","length":1548,"tagName":"div"}]